{
    "clinical_study": {
        "@rank": "18477", 
        "acronym": "PHAGOBURN", 
        "arm_group": [
            {
                "arm_group_label": "E. coli, Standard of care : Silver Sulfadiazine", 
                "arm_group_type": "Active Comparator", 
                "description": "Burn wounds infected by E. coli treated with Standard of care : Silver Sulfadiazine"
            }, 
            {
                "arm_group_label": "E. coli, Phages cocktail", 
                "arm_group_type": "Experimental", 
                "description": "Burn wounds infected by E. coli treated with Pherecydes Pharma Phages cocktail"
            }, 
            {
                "arm_group_label": "P. aeruginosa, Standard of care : Silver Sulfadiazine", 
                "arm_group_type": "Active Comparator", 
                "description": "Burn wounds infected with P. aeruginosa treated with Standard of care : Silver Sulfadiazine"
            }, 
            {
                "arm_group_label": "P. aeruginosa, Phages cocktail", 
                "arm_group_type": "Experimental", 
                "description": "Burn wounds infected by P. aeruginosa treated treated with Pherecydes Pharma Phages cocktail"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of PHAGOBURN is to assess tolerance and efficacy of local bacteriophage\n      treatment of E. coli or P. aeruginosa wound infections in burned patients."
        }, 
        "brief_title": "Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas Aeruginosa Wound Infections in Burned Patients", 
        "condition": "Wound Infection", 
        "condition_browse": {
            "mesh_term": [
                "Pseudomonas Infections", 
                "Wound Infection"
            ]
        }, 
        "detailed_description": {
            "textblock": "PHAGOBURN is a Phase I/II clinical trial randomized, multicentric, open label, standard of\n      care (Silver Sulfadiazine) controlled aiming at assessing tolerance and efficacy of local\n      bacteriophage treatment of wound infections due to E. coli or P. aeruginosa in burned\n      patients using Pherecydes Pharma anti-Escherichia coli and anti-Pseudomonas aeruginosa\n      bacteriophage cocktails GMP produced. This project is a European Research & Development\n      (R&D) project funded by the European Commission under the 7th Framework Programme for\n      Research and Development. This project is involving 7 clinical sites in EU."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Man or woman\n\n          -  Adult Informed consent obtained from patient or next of kin\n\n          -  In-hospital patient treated for burn wounds in a burn unit\n\n          -  Burn wound (grafted or not) or graft harvesting area, presenting local signs of\n             infection defined by SFETB criteria:\n\n               -  A local or loco-regional inflammatory reaction;\n\n               -  And/or an adverse and unexpected local evolution;\n\n               -  And/or regarding burn wounds: presence of pus, fast spontaneous debridement and\n                  separation, occurrence of blackish spots (necrosis or haemorrhage), unexplained\n                  conversion from a superficial lesion to a deep one (> 48th hour);\n\n               -  And/or regarding graft donor sites: presence of pus, unexplained delay in\n                  epidermisation, bedsore;\n\n               -  And/or regarding graft recipient sites: presence of pus, lysis of grafts,\n                  necrosis of fat located under the graft.\n\n          -  Burn wounds with a microbiologically documented infection, as defined by positive\n             surface swab, due to Escherichia coli or Pseudomonas aeruginosa whatever their\n             resistance profile\n\n          -  Treated by povidone-iodine\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding woman\n\n          -  Intercurrent condition requiring a treatment which may interfere with analysis\n             results: such as high dose of chronic corticotherapy, immunosuppressive medication,\n             oncologic chemotherapy\n\n          -  Patient included in an interventional research protocol with therapeutic intervention\n             still ongoing upon inclusion time or having participated into anti-infective drug\n             trials during the previous month.\n\n          -  Patient considered as part of a vulnerable population\n\n          -  Patient for whom treatment limitation or withdrawal during study period is considered\n\n          -  Allergy to Silver Sulfadiazine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "April 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02116010", 
            "org_study_id": "PHAGOBURN"
        }, 
        "intervention": [
            {
                "arm_group_label": "E. coli, Phages cocktail", 
                "description": "Use of Pherecydes Pharma Phages cocktail to treat respectively E. coli burn wound infection", 
                "intervention_name": "E. coli Phages cocktail", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "E. coli, Standard of care : Silver Sulfadiazine", 
                    "P. aeruginosa, Standard of care : Silver Sulfadiazine"
                ], 
                "description": "Use of Standard of care : Silver Sulfadiazine, to treat E. coli or P. aeruginosa infected burn wound", 
                "intervention_name": "Standard of care : Silver Sulfadiazine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "P. aeruginosa, Phages cocktail", 
                "description": "Use of Pherecydes Pharma Phages cocktail to treat P. aeruginosa burn wound infection", 
                "intervention_name": "P. Aeruginosa, Phages cocktail", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Silver Sulfadiazine", 
                "Sulfadiazine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Wound Infection in burned patient", 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jean-paul.pirnay@mil.be", 
                    "last_name": "Jean-Paul Pirnay, PhD", 
                    "phone": "+32 2 264 4844"
                }, 
                "facility": {
                    "address": {
                        "city": "Brussel", 
                        "country": "Belgium", 
                        "zip": "B-1120"
                    }, 
                    "name": "Hopital Militaire Reine Astrid"
                }, 
                "investigator": {
                    "last_name": "Serge Jennes, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "afrousseau@chu.ulg.ac.be", 
                    "last_name": "Anne-Fran\u00e7oise Rousseau, MD", 
                    "phone": "+32 4 3667495"
                }, 
                "facility": {
                    "address": {
                        "city": "Liege", 
                        "country": "Belgium"
                    }, 
                    "name": "CHU Sart-Tilman"
                }, 
                "investigator": {
                    "last_name": "Anne-Fran\u00e7oise Rousseau, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "patrick.jault@santarm.fr", 
                    "last_name": "Patrick Jault, MD", 
                    "phone": "+33 (0)1 41 46 62 13"
                }, 
                "contact_backup": {
                    "email": "thomas.leclerc@m4x.org", 
                    "last_name": "Thomas Leclerc, MD", 
                    "phone": "+33 (0)1 41 46 62 13"
                }, 
                "facility": {
                    "address": {
                        "city": "Clamart", 
                        "country": "France", 
                        "zip": "92141"
                    }, 
                    "name": "H\u00f4pital d'instruction des arm\u00e9es Percy"
                }, 
                "investigator": [
                    {
                        "last_name": "Patrick Jault, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Thomas Leclerc, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "fravat@ch-stjoseph-stluc-lyon.fr", 
                    "last_name": "Fran\u00e7ois Ravat, MD", 
                    "phone": "+33 (0) 478 618 925"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "F-69365"
                    }, 
                    "name": "Centre hospitalier ST Joseph et St Luc"
                }, 
                "investigator": {
                    "last_name": "Fran\u00e7ois Ravat, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "gregory.resch@unil.ch", 
                    "last_name": "Gr\u00e9gory Resch, PhD", 
                    "phone": "+41 21 692 56 23"
                }, 
                "facility": {
                    "address": {
                        "city": "Lausanne", 
                        "country": "Switzerland", 
                        "zip": "CH-1011"
                    }, 
                    "name": "Centre Hospitalier Universitaire Vaudois"
                }, 
                "investigator": {
                    "last_name": "Yok-Ai Que, Mer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "France", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "Phase I/II Clinical Trial Randomized, Multicentric, Open Label, Standard of Care (Silver Sulfadiazine) Controlled Aiming at Assessing Tolerance and Efficacy of Local Bacteriophage Treatment of Wound Infections Due to E. Coli or P. Aeruginosa in Burned Patients Using Pherecydes Pharma Anti-Escherichia Coli and Anti-Pseudomonas Aeruginosa Bacteriophages GMP Produced Cocktails . This Project is a European Research & Development (R&D) Project Funded by the European Commission Under the 7th Framework Programme for Research and Development Involving 7 Clinical Sites in EU.", 
        "overall_contact": {
            "email": "patrick.jault@santarm.fr", 
            "last_name": "Patrick Jault, MD", 
            "phone": "+33 1 41 46 62 13"
        }, 
        "overall_contact_backup": {
            "email": "christine.cotton@statitec.com", 
            "last_name": "Christine Cotton", 
            "phone": "+335 61 00 13 55"
        }, 
        "overall_official": {
            "affiliation": "Service de Sant\u00e9 des Arm\u00e9es, Hopital Percy (Clamart, France)", 
            "last_name": "Patrick Jault, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Belgium : Agence F\u00e9d\u00e9rale des M\u00e9dicaments et des Produits de Sant\u00e9", 
                "Switzeland : Suissmedic, Institut Suisse des produits th\u00e9rapeutiques"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time necessary for a persistent bacteria reduction of two modes or persistent bacteria eradication relative to D0 adjusted on antibiotic treatment (active on targeted strain) introduced between D1 to D7. Bacteria count performed on bacteria targeted by the phages cocktail collected from surface swab samples assessed by the microbiologist.", 
            "measure": "Time for bacteria reduction adjusted on antibiotic treatment", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02116010"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse events frequencies will be assessed in each treatment arms. Phages therapy safety profile will be compared to safety profile of standard of care .", 
                "measure": "Assessment of tolerance of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }, 
            {
                "description": "The criteria will be assessed according to wound clinical examination and bacteria count by the microbiologist.", 
                "measure": "Incidence an delay of infection reduction with different bacterial species from the targets", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "The number of infected burns or infected wounds getting a clinical improvement will be described and compared between treatment groups.", 
                "measure": "number of sites cured", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }
        ], 
        "source": "Pherecydes Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pherecydes Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}